Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

February 1, 2023

Conditions

COVID-19Chronic Kidney Disease stage4Chronc Kidney Disease Stage 5

Interventions

DRUG

Nirmatrelvir/ritonavir

Nirmatrelvir-ritonavir (Paxlovid)

Trial Locations (1)

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin

All Listed Sponsors

lead

Chinese University of Hong Kong

OTHER